Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...

Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed to confirm that.

From 2000 to 2019, definitive treatment for those with intermediate- or high-risk disease and limited life expectancy increased.

Researchers sought to determine trends in participation and detection of CRC in multiround FIT-based CRC screening.

Cadonilimab plus chemotherapy, with or without bevacizumab, could be a safe and effective treatment option, according to researchers.

Researchers sought to determine whether cilta-cel would have similar results in a real-world RRMM population as in a clinical trial population.

In a post hoc analysis of the phase 3 VISION trial, investigators analyzed PSA decline and clinical and patient-reported outcomes in patients with mCRPC receiving 177Lu-PSMA-617.

Suboptimal rates of dMMR testing and immunotherapy use suggest “a need for ongoing clinician and patient education, given the survival benefit of immunotherapy in recurrent endometrial cancer,” ...

Authors recommend patient and physician education and changes to practice guidelines and payment to overcome barriers to palliative care use.

The researchers found that stratification of patients with T-ALL into low- or high-risk of relapse could be achieved using 15 genomic imbalances as a threshold. Whole-genome analysis (WGA) identified ...

HealthDay News — Newly diagnosed pancreatic cancer patients receiving palliative care (PC) consultations have an increased prevalence of anxiety and depression, according to a study recently published ...

Investigators explored the role of treatment intensification with androgen receptor pathway inhibitors in patients with high-risk localized prostate cancer.